ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate

Stock News

昨天

ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.

The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1108389066"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108389066\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108389066?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108389066","market":"sh","top_or_hot":-1,"title":"ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate","media":"Stock News","content":"<p><b>ST Renfu (600079.SH)</b> announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.<br><br>The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-09-03 16:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>ST Renfu (600079.SH)</b> announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.<br><br>The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"證金概念","start_time":0,"source_url":"","article_id":"1108389066","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108389066","pubTimestamp":1788423398,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600079":"ST人福","BK0012":"证金概念","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","MDTX":"Corgi MediaTek 2x Daily ETF","BK0096":"民营医院","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0070":"员工持股","BK0188":"融资融券"},"translate_title":"ST人福启动新型术后疼痛候选药物II期临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":1,"IBBQ":1,"IBBJ":1,"MDTX":1,"BMED":1,"PSYK":1},"content_text":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}